BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: There remain many unanswered questions and ongoing clinical trials exploring BCL2 inhibitors as well as other agents to specifically target quiescent stem cell populations, and increasing use of STAMP inhibitors for refractory cases are likely to improve outcomes in CML (Jabbour and Kantarjian, 2020).